Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome

Hypertension

Volumn 59, Issue 4, 2012, Pages 893-898

  Ayers, Katie ^a   Byrne, Loretta M ^a   Dematteo, Anthony ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antihypertensive therapy; cardiovascular pathophysiology; clinical science; hypertension; insulin resistance

Indexed keywords

ANGIOTENSIN I; CYCLIC GMP; GLUCOSE; INSULIN; ISOPROSTANE DERIVATIVE; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DISPOSITION; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART RATE; HUMAN; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BENZOPYRANS; BLOOD GLUCOSE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ETHANOLAMINES; F2-ISOPROSTANES; FEMALE; HEART RATE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METOPROLOL; MIDDLE AGED; OXIDATIVE STRESS; PLASMINOGEN INACTIVATORS;

EID: 84858706089     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.189589     Document Type: Article

References (41)

1. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011;378:815-825.
2. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716. (Pubitemid 35403784)
3. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino RB Sr, Wang TJ, Vasan RS. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984-992. (Pubitemid 47329563)
4. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262:157-172. (Pubitemid 47090159)
5. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs. 2004;64:2537-2565. (Pubitemid 39591650)
6. The DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562. (Pubitemid 44550032)
7. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477-1490.
8. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension. 1998;32:965-971. (Pubitemid 29001421)
9. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension. 2002;40:859-865. (Pubitemid 35434907)
10. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab. 2002;87:448-452. (Pubitemid 34158202)
11. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with twoβ-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489-494. (Pubitemid 26161099)
12. Boman K, Boman JH, Andersson J, Olofsson M, Dahlof B. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. Clin Appl Thromb Hemost. 2010;16:146-152.
13. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236. (Pubitemid 39473160)
14. Gudbjornsdottir S, Fowelin J, Elam M, Attvall S, Bengtsson BA, Marin P, Lonnroth P. The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormone levels in hypertensive subjects. Eur J Clin Invest. 1997;27:29-35. (Pubitemid 27065170)
15. Koyama Y, Kodama K, Suzuki M, Harano Y. Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Am J Hypertens. 2002;15:927-931. (Pubitemid 35217396)
16. Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, Godicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2004;112:315-322. (Pubitemid 38849842)
17. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, Yilmaz MI, Ozcan O, Yaman H, Isik E, Fici F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591-596. (Pubitemid 43261924)
18. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van NL, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an l-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
19. Broeders MA, Doevendans PA, Bekkers BC, Bronsaer R, van GE, Heemskerk JW, Egbrink MG, van BE, Reneman RS, van Der ZR. Nebivolol: a third- generationβ-blocker that augments vascular nitric oxide release: endothelialβ(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 2000;102:677-684. (Pubitemid 30640669)
20. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 1998;18:1771-1779. (Pubitemid 28521068)
21. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904. (Pubitemid 43739401)
22. Yilmaz MB, Erdem A, Yalta K, Turgut OO, Yilmaz A, Tandogan I. Impact ofβ-blockers on sleep in patients with mild hypertension: a randomized trial between nebivolol and metoprolol. Adv Ther. 2008;25:871-883.
23. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6:45-86.
24. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA. 1990;87:9383-9387. (Pubitemid 120030630)
25. Hjalmarson A, Fagerberg B. MERIT-HF mortality and morbidity data. Basic Res Cardiol. 2000;95:I98-I103.
26. Fonseca V, Sharma PP, Shah M, Deedwania P. Risk of new-onset diabetes mellitus associated withβ-blocker treatment for hypertension. Curr Med Res Opin. 2011;27:799-807.
27. Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460-463. (Pubitemid 29417735)
28. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19:1429-1435. (Pubitemid 32730460)
29. Tarighi B, Kurum T, Demir M, Azcan SN. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients. Can J Cardiol. 2007;23:651-655. (Pubitemid 47177079)
30. Vyssoulis GP, Marinakis AG, Aznaouridis KA, Karpanou EA, Arapogianni AN, Cokkinos DV, Stefanadis CI. The impact of third-generationβ-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am J Hypertens. 2004;17:582-589. (Pubitemid 38844984)
31. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998;273: 8225-8231. (Pubitemid 28168879)
32. Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-lowdensity lipoproteins, and fatty acids. Coron Artery Dis. 1996;7:813-817. (Pubitemid 27020353)
33. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol. 2005;25:279-286. (Pubitemid 40189146)
34. Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A, Wachsman JT, Ames BN, Basu S, Brot N, FitzGerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med. 2005;38:698-710. (Pubitemid 40249740)
35. Flammer AJ, Hermann F, Wiesli P, Schwegler B, Chenevard R, Hurlimann D, Sudano I, Gay S, Neidhart M, Riesen W, Ruschitzka F, Luscher TF, Noll G, Lehmann R. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens. 2007;25:785-791. (Pubitemid 46398873)
36. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007;20:777-783. (Pubitemid 46936169)
37. Fahlbusch SA, Tsikas D, Mehls C, Gutzki FM, Boger RH, Frolich JC, Stichtenoth DO. Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers. Eur J Clin Pharmacol. 2004;60:83-88. (Pubitemid 38656126)
38. Fratta PA, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo C, Lo C, Cominacini L. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589-596. (Pubitemid 40684718)
39. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frolich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol. 2000;50:377-379.
40. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;2:823-827. (Pubitemid 11017550)
41. Lindholm LH, Carlberg B, Samuelsson O. Shouldβblockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553. (Pubitemid 41540112)